Tessera Therapeutics, a biotech developing a new approach to genome engineering, has entered into an agreement with the Bill & Melinda Gates Foundation to jointly fund the company’s in vivo programme for sickle cell disease (SCD).

The funding includes an initial investment, with potential total investment of up to $50 million, from the Gates Foundation intended to support the development of Tessera’s SCD programme into the clinic. The investment will support Tessera’s efforts towards advancing a SCD treatment and help further its objectives to develop transformative genetic medicines that are accessible globally.

Tessera is developing Gene Writers, a platform for SCD designed to enable a true correction of the sickle mutation to wild-type with one-time intravenous administration in vivo, without the need for complex stem cell mobilisation or toxic chemotherapy conditioning. Critical in enabling in vivo therapies, Tessera is leveraging its non-viral delivery platform to develop lipid nanoparticles targeting delivery of Gene Writers to long-term hematopoietic stem cells.

“Sickle cell disease patients globally remain deeply underserved by existing treatment options. We are excited to develop what we believe will be a disruptive one-time curative treatment for SCD that is safer, easier, and more scalable than ex vivo genetic approaches,” said Michael Severino, CEO of Tessera Therapeutics. “We look forward to advancing a genetic medicine that can potentially reshape the treatment landscape for sickle cell disease worldwide.”

Megan Thomas, Multimedia Editor, DDW